Large Segmentation Radiotherapy ± Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer

NCT ID: NCT06660628

Last Updated: 2024-10-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

348 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-21

Study Completion Date

2034-08-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a single-center, prospective, non-randomized controlled study. The primary objective is to examine the clinical outcomes of utilizing Deep Inspiration Breath Hold (DIBH) in conjunction with hypo-fractionated radiotherapy for patients diagnosed with left-sided breast cancer with a particular focus on its potential to reduce the incidence of cardiac-related clinical and subclinical events.Participants will revieve large segmentation sadiotherapy ± DIBH for left breast cancer and be followed up to gather their clinical cardiac imformation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Surface guided radiation therapy (SGRT) combined with Deep Inspiration Breath Hold (DIBH) technique

Patients with left breast cancer treated with Surface guided radiation therapy (SGRT) combined with Deep Inspiration Breath Hold (DIBH) technique

Group Type EXPERIMENTAL

Large Segmentation Radiotherapy

Intervention Type RADIATION

Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold

DIBH

Intervention Type DEVICE

Deep Inspiration Breath Hold

Surface guided radiation therapy

Intervention Type DEVICE

The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.

laser alignment combined with free breathing treatment

Patients with left breast cancer treated with traditional laser alignment with free breathing treatment

Group Type ACTIVE_COMPARATOR

Large Segmentation Radiotherapy

Intervention Type RADIATION

Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold

laser alignment

Intervention Type DEVICE

Laser systems for virtual simulation and patient positioning in radiotherapy

free breathing

Intervention Type BEHAVIORAL

Patients breathe calmly while radiotherapy instead of holding their breath.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Large Segmentation Radiotherapy

Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold

Intervention Type RADIATION

DIBH

Deep Inspiration Breath Hold

Intervention Type DEVICE

Surface guided radiation therapy

The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.

Intervention Type DEVICE

laser alignment

Laser systems for virtual simulation and patient positioning in radiotherapy

Intervention Type DEVICE

free breathing

Patients breathe calmly while radiotherapy instead of holding their breath.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18-70 years old, female, life expectancy \> 5 years
2. ECOG 0, 1, 2 points
3. Pathologically diagnosed with left breast cancer and underwent breast-conserving surgery or modified radical mastectomy
4. The patient will receive radiation therapy to the entire breast or chest wall ± the lymphatic drainage area above and below the clavicle ± the lymphatic drainage area in the axilla.
5. No prior neoadjuvant chemotherapy or breast reconstruction.
6. No active cardiac disease, myocardial infarction, or congestive cardiac failure at baseline.
7. Patients can hold their breath for at least 30 seconds after training
8. Patients who can be followed up and agree to follow the plan.
9. Sign the consent form.

Exclusion Criteria

1. Lesions were observed on both sides of the breast.
2. Diagnosis could not be confirmed by pathology.
3. Distant metastasis was identified.
4. The patient had undergone neoadjuvant chemotherapy or breast reconstruction surgery.
5. Severe cardiac insufficiency; myocardial infarction or uncorrected unstable cardiac arrhythmia or uncorrected unstable angina within the last 3 months; or pericardial disorders
6. The patient's New York Heart Association (NYHA) cardiac classification is within categories 2-4.
7. A history of chronic lung disease, including conditions that may contribute to ductal dilatation, such as chronic obstructive pulmonary disease (COPD) and interstitial pneumonia.
8. Previous mediastinal radiotherapy.
9. Previous or concurrent second primary malignant tumor (except skin cancer that is not a malignant black pigmented tumor, papillary/follicular carcinoma of the thyroid, carcinoma in situ of the cervix, and contralateral non-invasive breast cancer).
10. Irradiation of the lymphatic drainage area of the internal breast is required.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking Union Medical College Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xiaorong Hou

Role: CONTACT

+86 13811963013

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiaorong Hou

Role: primary

+86 13811963013

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-PUMCH-B-116

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

K6433

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Breast Cancer Lung Late Effects
NCT02725840 COMPLETED